Dashboard
Company has a low Debt to Equity ratio (avg) at times
Low Debt Company with Strong Long Term Fundamental Strength
The company has declared Positive results for the last 7 consecutive quarters
With ROCE of 9.26%, it has a expensive valuation with a 2.84 Enterprise value to Capital Employed
Stock DNA
Industrial Manufacturing
USD 36,213 Million (Mid Cap)
35.00
NA
103.74%
0.09
8.72%
3.27
Total Returns (Price + Dividend) 
Xylem, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is Xylem, Inc. overvalued or undervalued?
As of 31 October 2025, the valuation grade for Xylem, Inc. has moved from very expensive to expensive, indicating a slight improvement in perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 35, a Price to Book Value of 3.03, and an EV to EBITDA of 20.21. In comparison, peers such as Ingersoll Rand, Inc. have a significantly higher P/E of 52.55, while Dover Corp. is at 43.35, suggesting that Xylem's valuation is not as extreme as some competitors but still elevated. Despite a strong year-to-date return of 29.02% compared to the S&P 500's 16.30%, Xylem's longer-term performance has lagged behind, with a 5-year return of 63.40% versus the S&P 500's 109.18%. This discrepancy reinforces the notion that while Xylem has performed well recently, its current valuation may not be justified given its relative performance and the valuation metrics compared to its pee...
Read MoreIs Xylem, Inc. overvalued or undervalued?
As of 31 October 2025, the valuation grade for Xylem, Inc. has moved from very expensive to expensive, indicating a slight improvement in perceived value. Despite this change, the company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 35, an EV to EBITDA of 20.21, and a Price to Book Value of 3.03, all of which suggest that the stock is trading at a premium compared to its peers. In comparison, Ingersoll Rand, Inc. has a higher P/E ratio of 52.55, while Dover Corp. is more fairly valued with a P/E of 43.35. This places Xylem in a relatively expensive position within its industry. Additionally, while Xylem has shown strong returns, with a year-to-date return of 30.02% compared to the S&P 500's 16.30%, its three-year return of 47.27% lags behind the S&P 500's 76.66%. This performance suggests that, despite recent gains, the stock's valuation may not be justified in t...
Read MoreIs Xylem, Inc. overvalued or undervalued?
As of 31 October 2025, the valuation grade for Xylem, Inc. has moved from very expensive to expensive, indicating a slight improvement in perceived value. However, the company remains overvalued based on its current metrics. The P/E ratio stands at 35, significantly higher than the industry average, while the EV to EBITDA ratio is 20.21, and the PEG ratio is 1.10, suggesting that the stock is priced for growth that may not materialize. In comparison to its peers, Xylem, Inc. has a P/E ratio of 37.49, which is higher than Dover Corp.'s fair valuation at 43.35 and significantly lower than Ingersoll Rand, Inc.'s very expensive rating at 52.55. The company's recent performance shows a 30.02% return year-to-date, outperforming the S&P 500's 16.30% in the same period, but it lags behind the S&P 500 over longer horizons, particularly in the 3-year and 5-year returns. Overall, Xylem, Inc. appears to be overvalued ...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Foreign Institutions
Held in 150 Schemes (29.87%)
Held by 445 Foreign Institutions (38.7%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 11.47% vs -8.50% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 34.13% vs -48.77% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 16.23% vs 32.95% in Dec 2023
YoY Growth in year ended Dec 2024 is 46.14% vs 71.55% in Dec 2023






